A Phase 1b/2 Dose Escalation and Expansion Trial of NC-6004 (Nanoparticle Cisplatin) Plus Gemcitabine in Patients With Advanced Solid Tumors or Non-Small Cell Lung, Biliary Tract, and Bladder Cancer

Trial Profile

A Phase 1b/2 Dose Escalation and Expansion Trial of NC-6004 (Nanoparticle Cisplatin) Plus Gemcitabine in Patients With Advanced Solid Tumors or Non-Small Cell Lung, Biliary Tract, and Bladder Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 27 Oct 2017

At a glance

  • Drugs Cisplatin (Primary) ; Gemcitabine
  • Indications Biliary cancer; Bladder cancer; Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors NanoCarrier
  • Most Recent Events

    • 27 Oct 2017 Results published in a NanoCarrier media release.
    • 18 Oct 2017 Results (n=22 phase Ib) presented at the 18th World Conference on Lung Cancer
    • 13 Oct 2017 According to results published in the Clinical cancer research: an official journal of the American Association for Cancer Research, a protocol has been amended to add orally or intravenously supplements of magnesium sulfate (8 mEq) during pre-hydration regimen and as needed if magnesium levels decreased to less than 1.8 mg/dL or the lower limit of normal
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top